Reid Hoffman Leaves Microsoft Board As Manus Pulls AI Drug Discovery Into Focus

BySendTech Times AI & Enterprise DeskNewsroom-edited, source-reviewed coverage|Source: Thenextweb

Newsroom brief

Reid Hoffman is leaving Microsoft’s board after nearly a decade to focus on Manus, the AI-powered drug discovery startup he co-founded. Manus has raised over $50 million across two seed rounds, with General Catalyst among its backers and Dr. Siddhartha Mukherjee serving as CEO. The next signal is whether Manus can turn Hoffman’s founder focus into source-backed drug discovery milestones beyond early funding and AI positioning.

Verified against source materialEdited by SendTech Times AI & Enterprise Desk

Reid Hoffman Leaves Microsoft Board As Manus Pulls AI Drug Discovery Into Focus

Image source: TNW

Reid Hoffman is leaving Microsoft’s board after nearly a decade as he shifts attention toward Manus, the AI-powered drug discovery startup he co-founded.

Microsoft Loses A Board Member With Direct AI Startup Exposure

Microsoft said in a Thursday regulatory filing that Hoffman is stepping down from the board.

He is shifting toward Manus, where he holds the title of co-founder and chairman rather than CEO.

The move matters for Microsoft because Hoffman’s board tenure sat alongside several AI-linked relationships around the company.

He joined the board in 2016 after Microsoft’s $26.2 billion LinkedIn acquisition.

In 2019, he was still a director when Microsoft made its initial $1 billion OpenAI investment.

Hoffman was also an early OpenAI investor and remained on its board until 2023.

He left that role citing potential conflicts of interest, and those questions later widened around Microsoft’s $650 million acqui-hire deal with Inflection AI, the startup Hoffman co-founded.

Manus Becomes The Strategic Focus

Manus is the company now taking Hoffman’s attention.

It has secured more than $50 million in two seed financings, and General Catalyst is among the named backers.

Dr. Siddhartha Mukherjee, described as a physician, biologist and Pulitzer Prize-winning author of “The Emperor of All Maladies,” is CEO.

Hoffman said on a recent episode of his “Possible” podcast that Manus is making enough progress to pull him back into a more active founder role.

“I need to get back to founder mode,” Hoffman told Microsoft CEO Satya Nadella during the conversation.

AI Drug Discovery Gets A Governance Signal

Hoffman said Manus is working on what he calls “Move 37” AI, a term borrowed from AlphaGo’s famous move against Lee Sedol and applied here to chemistry and the search for novel compounds to combat cancer.

The broader signal is not only about one board resignation.

It shows how AI drug discovery is becoming a more active focus for investors and company builders who also have ties to major platform companies.

ByteDance’s Anew Labs recently presented its first AI-designed therapy, while Google DeepMind’s Isomorphic Labs has AI-designed drug candidates entering clinical trials.

The next signal is whether Manus can turn its funding and founder attention into drug discovery milestones that are specific enough for partners, regulators or clinical development.

#drug discovery #Microsoft #Manus #Reid Hoffman

Listen Labs Raises $69 Million to Scale AI Customer Interviews

Listen Labs raised $69 million after running more than one million AI-powered interviews, testing whether AI moderation can speed up customer research without sacrificing participant quality.

Rekise Marine’s $9.7 Million Seed Round Puts India’s Autonomous Vessel Stack In Focus

Rekise Marine raised $9.7 million in seed funding led by Accel and NKSquared, giving the Bengaluru marine robotics startup capital to finish sea trials for Jalkapi, deepen its autonomy software and hire across robotics, AI/ML and naval architecture.

Kodesage Raises $6.6M for AI Legacy-Code Modernization in Regulated Sectors

Kodesage closed a $6.6 million seed round to expand an AI platform for modernizing on-premises legacy software. VentureFriends led the round, with Portfolion participating, as the company targets regulated sectors that keep critical workloads inside controlled environments. The practical question is whether Kodesage can turn code discovery, documentation and conversion automation into named customer deployments across the U.S. and Europe.

OpenAI Researcher Disputes $2B AI Drug Startup Report

TechCrunch reported that OpenAI researcher Miles Wang is leaving to form an AI drug-discovery startup and is in talks to raise about $200 million at a $2 billion valuation. Wang disputed the funding figures and company description, while final deal terms, named co-founders and a launch date remain outside the report.

PixVerse Raises $439 Million As Video AI Valuation Tops $2 Billion

Singapore-based PixVerse has raised $439 million across a Series C extension and earlier funding, pushing its valuation above $2 billion, according to TechCrunch. The video-generation startup lists more than 150 million registered users and 15 million monthly active users, while paying-user totals, enterprise revenue and independent benchmark results remain outside the public record.

Pramaana Labs Raises $27 Mn to Make AI Prove Its Answers

Bengaluru-based Pramaana Labs raised $27 Mn in seed funding led by Khosla Ventures to build a verification layer for AI in regulated industries. The company says its system turns questions into formal statements, runs a proof engine and refuses to answer when a proof cannot be established. The financing points to a tougher enterprise AI test: whether models can support tax, law, finance and healthcare work where hallucinations carry legal risk.